Chemotherapy-induced PDL-1 expression in cancer-associated fibroblasts promotes chemoresistance in NSCLC

GH Palliyage, P Samart, S Bobbala, LW Rojanasakul… - Lung Cancer, 2023 - Elsevier
Objectives A cure for cancer is out of reach for most patients due to chemoresistance.
Cancer-associated fibroblasts (CAFs) play a vital role in cancer chemoresistance, but …

Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer

H Kim, HJ Kwon, SY Park, Y Park, E Park, JH Chung - PloS one, 2018 - journals.plos.org
In this study, we present the clinicopathological features associated with PD-L1 protein and
mRNA expression in a large Asian cohort of patients with non-small cell lung cancer …

PDL-1 expression in lung carcinoma and its correlation with clinicopathological and prognostic characteristics

M Farrag, E Ibrahim, H Abdelwahab… - … of Immunoassay and …, 2021 - Taylor & Francis
Lung cancers have high incidence and high mortality rates. The immune checkpoints as
programmed death ligand 1 (PDL-1) can suppress the tumor immune reaction. So, their …

[HTML][HTML] Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung …

Q Chen, YY Fu, QN Yue, Q Wu, Y Tang… - … Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
Background: Programmed death ligand 1 (PD-L1) was reported to predict the response of
immunotherapy; however, the association between PD-L1 expression and clinicopathologic …

p53 regulation of PDL1 is mediated through miR-34a

MA Cortez, D Valdecanas, X Wang, C Ivan, H Peltier… - Cancer Research, 2015 - AACR
Background Although clinical studies have shown promise for targeting PD1/PDL1 signaling
in non-small cell lung cancer (NSCLC), little is known of how PDL1 expression is regulated …

PDL1 Regulation by p53 via miR-34

MA Cortez, C Ivan, D Valdecanas… - Journal of the …, 2016 - academic.oup.com
Background: Although clinical studies have shown promise for targeting PD1/PDL1
signaling in non–small cell lung cancer (NSCLC), the regulation of PDL1 expression is …

[HTML][HTML] Prognostic and predictive value of PDL1 expression in breast cancer

R Sabatier, P Finetti, E Mamessier, J Adelaide… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied in
breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different …

Identification of PDL1‐Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors

Y Wu, L Lin, X Liu - Disease Markers, 2020 - Wiley Online Library
PD1/PDL1 inhibitors have been adopted for the treatment of advanced non‐small‐cell lung
cancer, and PDL1 expression has been investigated as a predictive biomarker for …

PDL1-expressing circulating tumor cells (CTCs) in head and neck squamous cell carcinoma (HNSCC).

G Koutsodontis, A Strati, M Avgeris, E Maratou… - 2015 - ascopubs.org
6018 Background: Blockade of PD-1/PD-L1 immune checkpoint pathway emerged as
promising novel therapeutic strategy for cancer. Predictive biomarkers for response to anti …

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer

J Sheng, W Fang, J Yu, N Chen, J Zhan, Y Ma… - Scientific reports, 2016 - nature.com
The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown.
The aim of this study was to investigate the impact of neoadjuvant chemotherapy (NACT) on …